Although recently introduced infection markers such as procalcitonin, several cytokines and markers like endothelin-1, copeptin and pro-adrenomedullin show promising results in risk assessment and outcome prediction the implementation of these “new” infection markers is hampered by validation, costs and accessibility. Here, AVP is linked to infection.